Market Overview:
The global hepatitis A virus cellular receptor 2 market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of hepatitis A virus infections, rising demand for novel therapies for the treatment of hepatitis A virus infections, and growing investments by pharmaceutical companies in research and development activities for the development of novel therapies for hepatitis A virus infections. However, patent expirations and generic competition are expected to restrain the growth of this market during the forecast period. The global hepatitis A virus cellular receptor 2 market can be segmented on the basis of type into IMM-1802, LY-3321367, MCLA-134, CA-170, CA-327, ENUM-005 and others. On the basis of application, this market can be segmented into colon cancer therapy; myelodysplastic syndrome therapy; non small cell lung cancer therapy; other applications such as hematopoietic stem cell transplantation (HSCT), solid tumors etc.; and regional markets.
Product Definition:
Hepatitis A Virus Cellular Receptor 2 is a cellular receptor that binds to the hepatitis A virus. This receptor is important for the virus to infect cells and replicate.
IMM-1802:
IMM-1802 is a small peptide, which is derived from the M2 muscarinic receptor. It was discovered by researchers at the University of Texas in San Antonio and has been patented by them.
"Peptides for vaccine development against Hepatitis A Virus (HAV) are encompassed by this invention wherein the peptides bind to HAV surface receptors.
LY-3321367:
LY-3321367 is a selective inhibitor of the voltage-gated Lck calcium channel. It has been studied in vitro and in vivo as an anti-viral agent for the treatment of Hepatitis A Virus (HAV). The compound potently inhibits viral replication at early stages of infection by blocking entry into host cells. Recently, it has been shown to be effective against both genotypes including 1 and 2 viruses.
Application Insights:
Based on the application, the global hepatitis A virus cellular receptor 2 market is segmented into colon cancer, myelodysplastic syndrome, non-small cell lung cancer, and others. The other applications include liver diseases such as chronic active hepatitis and primary biliary cirrhosis. Among these liver diseases, only hep A viruses are found to be circulating while no other viruses are observed in blood or tissues of patients suffering from chronic active hepatitis or primary biliary cirrhosis. This finding indicates that a patient's immune system has successfully cleared all other pathogens but still leaves a residual infection with hep A virus which causes inflammation in the liver resulting in disease progression.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing incidence of hepatitis A virus (HAV) infection, rising awareness about HAV vaccines, and availability of effective treatment methods for HAV infections.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing government initiatives for immunization against infectious diseases coupled with growing healthcare expenditure in emerging countries such as China and India. In addition, favorable reimbursement policies are also expected to boost revenue generation from this region during the same period. For instance, National Health Mission 2016-2017 under Indian Government's public health program covers vaccination against hepatitis A virus (HAV). This initiative covered more than 360 million people at a cost of USD X per person which was utilized towards purchase price of vaccine along with other components required for its production (HepA vaccine).
Growth Factors:
- Increasing incidence of hepatitis A virus infection
- Growing awareness about the benefits of early diagnosis and treatment
- Rising demand for better and more effective therapies for hepatitis A virus infection
- Technological advancements in the field of diagnostics and therapeutics
- Growing number of clinical studies on hepatits A virus cellular receptor 2
Scope Of The Report
Report Attributes
Report Details
Report Title
Hepatitis A Virus Cellular Receptor 2 Market Research Report
By Type
IMM-1802, LY-3321367, MCLA-134, CA-170, CA-327, ENUM-005, Others
By Application
Colon Cancer, Myelodysplastic, Non-Small Cell Lung Cancer, Others
By Companies
Aurigene Discovery Technologies Ltd, BeiGene Ltd, Eli Lilly and Co, Enumeral Biomedical Holdings Inc, Incyte Corp, Interprotein Corp, Jounce Therapeutics Inc, Merus NV, Novartis AG, Sorrento Therapeutics Inc, Sutro Biopharma Inc, Tesaro Inc, Trellis Bioscience Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Hepatitis A Virus Cellular Receptor 2 Market Report Segments:
The global Hepatitis A Virus Cellular Receptor 2 market is segmented on the basis of:
Types
IMM-1802, LY-3321367, MCLA-134, CA-170, CA-327, ENUM-005, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colon Cancer, Myelodysplastic, Non-Small Cell Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aurigene Discovery Technologies Ltd
- BeiGene Ltd
- Eli Lilly and Co
- Enumeral Biomedical Holdings Inc
- Incyte Corp
- Interprotein Corp
- Jounce Therapeutics Inc
- Merus NV
- Novartis AG
- Sorrento Therapeutics Inc
- Sutro Biopharma Inc
- Tesaro Inc
- Trellis Bioscience Inc
Highlights of The Hepatitis A Virus Cellular Receptor 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IMM-1802
- LY-3321367
- MCLA-134
- CA-170
- CA-327
- ENUM-005
- Others
- By Application:
- Colon Cancer
- Myelodysplastic
- Non-Small Cell Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hepatitis A Virus Cellular Receptor 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hepatitis A Virus Cellular Receptor 2 is a protein that helps the virus attach to cells.
Some of the major players in the hepatitis a virus cellular receptor 2 market are Aurigene Discovery Technologies Ltd, BeiGene Ltd, Eli Lilly and Co, Enumeral Biomedical Holdings Inc, Incyte Corp, Interprotein Corp, Jounce Therapeutics Inc, Merus NV, Novartis AG, Sorrento Therapeutics Inc, Sutro Biopharma Inc, Tesaro Inc, Trellis Bioscience Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hepatitis A Virus Cellular Receptor 2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hepatitis A Virus Cellular Receptor 2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hepatitis A Virus Cellular Receptor 2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hepatitis A Virus Cellular Receptor 2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hepatitis A Virus Cellular Receptor 2 Market Size & Forecast, 2020-2028
4.5.1 Hepatitis A Virus Cellular Receptor 2 Market Size and Y-o-Y Growth
4.5.2 Hepatitis A Virus Cellular Receptor 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 IMM-1802
5.2.2 LY-3321367
5.2.3 MCLA-134
5.2.4 CA-170
5.2.5 CA-327
5.2.6 ENUM-005
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colon Cancer
6.2.2 Myelodysplastic
6.2.3 Non-Small Cell Lung Cancer
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hepatitis A Virus Cellular Receptor 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hepatitis A Virus Cellular Receptor 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 IMM-1802
9.6.2 LY-3321367
9.6.3 MCLA-134
9.6.4 CA-170
9.6.5 CA-327
9.6.6 ENUM-005
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colon Cancer
9.10.2 Myelodysplastic
9.10.3 Non-Small Cell Lung Cancer
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 IMM-1802
10.6.2 LY-3321367
10.6.3 MCLA-134
10.6.4 CA-170
10.6.5 CA-327
10.6.6 ENUM-005
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colon Cancer
10.10.2 Myelodysplastic
10.10.3 Non-Small Cell Lung Cancer
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 IMM-1802
11.6.2 LY-3321367
11.6.3 MCLA-134
11.6.4 CA-170
11.6.5 CA-327
11.6.6 ENUM-005
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colon Cancer
11.10.2 Myelodysplastic
11.10.3 Non-Small Cell Lung Cancer
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 IMM-1802
12.6.2 LY-3321367
12.6.3 MCLA-134
12.6.4 CA-170
12.6.5 CA-327
12.6.6 ENUM-005
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colon Cancer
12.10.2 Myelodysplastic
12.10.3 Non-Small Cell Lung Cancer
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 IMM-1802
13.6.2 LY-3321367
13.6.3 MCLA-134
13.6.4 CA-170
13.6.5 CA-327
13.6.6 ENUM-005
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colon Cancer
13.10.2 Myelodysplastic
13.10.3 Non-Small Cell Lung Cancer
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hepatitis A Virus Cellular Receptor 2 Market: Competitive Dashboard
14.2 Global Hepatitis A Virus Cellular Receptor 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aurigene Discovery Technologies Ltd
14.3.2 BeiGene Ltd
14.3.3 Eli Lilly and Co
14.3.4 Enumeral Biomedical Holdings Inc
14.3.5 Incyte Corp
14.3.6 Interprotein Corp
14.3.7 Jounce Therapeutics Inc
14.3.8 Merus NV
14.3.9 Novartis AG
14.3.10 Sorrento Therapeutics Inc
14.3.11 Sutro Biopharma Inc
14.3.12 Tesaro Inc
14.3.13 Trellis Bioscience Inc
